Regeneron Pharmaceuticals is a biotechnology and biopharmaceutical company. Originally, the company focused on the regenerative capabilities of neutrophic factors, thus the name Regeneron. Today, their field of expertise also includes cytokine and tyrosine kinase receptors.
When it comes to technology platforms, Regeneron’s patented Trap technology helps create high-affinity product candidates for many types of signaling molecules, including cytokines and growth factors. The Trap technology makes it possible to fuse two receptor components and a immunoglobulin-G constant region (all fully human). Regeneron has also developed the VelociSuite which includes a number of patented technologies, such as VelociMab and VeloImmune. VelociSuite helps researchers select the most suitable targets for therapeutic intervention and generate the required antibodies.
Regeneron Pharmaceuticals are traded under the symbol REGN on Nasdaq Global Select Market. The common stock is included in the indices Nasdaq-100 and Nasdaq Biotechnology.
Purchasing shares directly from the company?
There is no direct stock purchase plan for stock in Regeneron Pharmaceuticals.
Dividends planned?
Regeneron Pharmaceuticals has never paid out cash dividends in the past, and the company has no plans for paying any dividends in the foreseeable future.
What is this company selling?
- The drug ARCALYST (rilonacept) was approved by the United States Food and Drug Administration (FDA) in 2008 for the treatment of cryopyrin-associated periodic syndromes (CAPS).
- EYLEA & ZALTRAP (aflibercept). Aflibercept is sold under the brand name EYLEA for the treatment of of wet macular degeneration (approved by US FDA in 2011) and under the brand name ZALTRAP for the treatment of metastatic colorectal cancer (approved by the US FDA in 2012).
- PRALUENT was approved by US FDA in 2015 for the treatments of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol.
Background & Future
- Regeneron was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., Alfred G. Gilman M.D., Ph.D. and Eric M. Shooter, Ph.D.
- Regeneron was incorporated in 1988 in New York State.
- Regeneron opens labs in Tarrytown, New York in 1989, and signs its first corporate collaboration.
- Regeneron publish their first paper in Science in 1990. It concerns cloning of a novel neurotrophic factor, and becomes the most highly cited neurobiology paper of the year. 1990 is also the year when Regeneron launches its Orphan Receptor program, and collaborates with Amgen to develop neurotrophic factors brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3).
- Regeneron has been a publicly traded company since April 1991, when it went public on the NASDAQ market.
- Clinical development of ARCALYST starts in 2000.
- Clinical development in oncology is commenced for VEGF Trap.
- In 2003, Regeneron publishes a first paper on VelociGene, thereby making their Veloci technologies known worldwide.
- Clinical development for neovascular wet age-related macular degeneration is started for VEGF Trap-Eye in 2004.
- Regeneron’s first fully-human antibody, one that targets IL-6R, enters clinical development in inflammatory disease in 2006.
- The drug ARCALYST (rilonacept) was approved by the United States Food and Drug Administration (FDA) in 2008 for the treatment of cryopyrin-associated periodic syndromes (CAPS).
- EYLEA (aflibercept) was approved by US FDA in 2011 for the treatment of wet macular degeneration.
- ZALTRAP (aflibercept) was approved by US FDA in 2012 for the treatment of metastatic colorectal cancer.
- PRALUENT was approved by US FDA in 2015 for the treatments of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD).
- In July 2015, Regeneron announced a new collaboration with the French pharmaceutical Sanofi S.A. Intended to discover, develop and commercialize new immuno-oncology drugs.
- At the time of writing, Regeneron has three products in stage-3 development. Sarilumab (REGN88) IL-6R antibody for the treatment of rheumatoid arthritis, REGN2222 RSV antibody for the treatment of respiratory syncytial virus, and Dupilumab (REGN668)
IL-4R antibody for the treatment of asthma as well as for atopic dermatitis in adults.
Practical info
| Company type | Public company |
| Industry | Biotechnology and biopharmaceutical |
| Traded as | NASDAQ: REGN |
| Founded | 1988 |
| Headquartered | Tarrytown, New York, USA |
| Website | Regeneron.com |
Contact information
Regeneron Pharmaceuticals
777 Old Saw Mill River Road
Tarrytown, NY 10591
USA
Phone #: +1-914-847-7000
Email address: invest@regeneron.com
Transfer agent
American Stock Transfer & Trust
59 Maiden Lane, Plaza Level
New York, NY 10038
USA
Phone #: (800) 937-5449